For patients with mucopolysaccharidosis type I (MPS I)

IMAGINE HOW FAR
 THEY COULD GO

In Study 1, at 26 weeks, 6 years and older patients treated with Aldurazyme® (laronidase) showed a mean 38m increase in distance walked (as measured by the 6‑MWT) and a mean 4‑point increase in percent predicted forced vital capacity (FVC) compared with those receiving placebo. All photos are actor portrayals, not actual patients.


ALDURAZYME® is indicated for adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis type I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms.1

Limitations of Use:

  • The risks and benefits of treating mildly affected patients with the Scheie form have not been established.
  • ALDURAZYME has not been evaluated for effects on the central nervous system manifestations of the disorder.

Explore Aldurazyme efficacy

LEARN MORE

Explore Aldurazyme safety

SEE MORE

Coverage options for Aldurazyme

LEARN ABOUT COVERAGE

6-MWT = six-minute walk test; FVC = forced vital capacity; MPS I = mucopolysaccharidosis type I.


Reference: 1. ALDURAZYME [prescribing information]. Cambridge, MA: Genzyme Corporation; 2020.